ERLONAT
Erlotinib hydrochloride is approved to be used alone or with other drugs to treat:
- Non-small cell lung cancer (NSCLC).
- It is used as first-line treatment for metastatic NSCLC in patients with tumors that have certain epidermal growth factor receptor (EGFR) mutations.
- It is used for locally advanced or metastatic NSCLC in patients who have already been treated with chemotherapy.
- Pancreatic cancer. It is used with gemcitabine hydrochloride in patients whose disease cannot be removed by surgery or has metastasized.
ERLONAT AVAILABLE AS: 100,150MG tablets. (30 Tab Bottle ) MANUFACTURE BY: NATCO (INDIA) |
Recommended Dose:
Oral
Locally advanced or metastatic non-small cell lung carcinoma
Adult: 150 mg once daily until disease progression or unacceptable toxicity. Reduce dose in decrements of 50 mg when necessary.
Oral
Locally advanced, unresectable or metastatic pancreatic cancer
Adult: As 1st-line treatment with gemcitabine: 100 mg once daily, reduce dose in decrements of 50 mg when necessary.
Consult your doctor for proper Dosage for yourself